Previous 10 | Next 10 |
home / stock / wxibf / wxibf news
2023-05-04 05:21:00 ET Summary Baron Emerging Markets Fund gained 2.68% (Institutional Shares) during the first quarter of 2023, while its principal benchmark Index, the MSCI EM Index, returned 3.96%. The Fund may invest in companies of any market capitalization, and we have gener...
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
Summary WuXi Biologics outlicensed global rights for up to four pre-clinical bi- and multi-specific TCE antibodies to GSK in a $1.5 billion agreement. ArriVent Biopharma of Philadelphia is raising another $145 million to bring drugs from China and other emerging biotech hubs to the US m...
Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund (the “Fund”) declined 16.18% (Institutional Shares) during the second quart...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Emerging Markets Fund (the “Fund”) declined 10.33% (Institutional Shares) during the second quarter o...
Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...
WuXi Biologics ( OTCPK:WXXWY ) ( OTCPK:WXIBF ) gained nearly 12% on Tuesday after Reuters reported that the Wuxi, China-based life sciences company is one step closer to getting off the U.S. Commerce Department's "Unverified List." According to a department official, C...
We had previously owned WuXi Biologic shares but sold it in the second quarter of 2019. We bought back WXIBF stock after a sharp price correction in the first quarter of 2021. The rapid development of several antibody drugs for COVID-19 gave a further, unexpected boost to WuXi...
Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989. Stock markets fell in the quarter, as the world watched in horror Russia’s invasion of Ukraine. China-based WuXi Biologics illustrates the perf...
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc Company Name:
WXIBF Stock Symbol:
OTCMKTS Market:
U.S. intelligence officials have informed senators that WuXi AppTec Co Ltd (OTC:WXIBF), a Chinese pharmaceutical company, allegedly transferred U.S...
The pharmaceutical market reached a total value of US$1.27 trillion in 2020, according to data from Statista , up significantly from US$887 billion in 2010. By 2025, that value is expected to increase even further to an estimated US$1.6 billion. Experienced and novice invest...
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures NEW JERSEY and HANGZHOU, CHINA, July 15, 2021 - (ACN Newswire) - Adlai Nortye Ltd. (hereinafter referred to as "...